Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242710 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
A Phase 3 study of Osteoporosis and Endometrial Hyperplasia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,083
- Enrollment target
- 9
- Study locations
NCT00242710: Completed Phase 3 study of Osteoporosis and Endometrial Hyperplasia, sponsored by Pfizer.
NCT00242710 is a Phase 3 study of Osteoporosis and Endometrial Hyperplasia that has completed, run by Pfizer. The registered enrollment target is 1,083 participants, below the 1,533-participant average among 84 other Osteoporosis trials with a reported enrollment target (29% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242710, a Phase 3 study of Osteoporosis and Endometrial Hyperplasia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,083 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
Primary Outcome
Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bazedoxifene/Conjugated Estrogen
- DRUG CE 0.45 mg/MPA 1.5mg
Study Locations (9)
Florida
- Pfizer Investigational Site - Inverness
- Pfizer Investigational Site - West Palm Beach
California
- Pfizer Investigational Site - Upland
Georgia
- Pfizer Investigational Site - Decatur
Hawaii
- Pfizer Investigational Site - Honolulu
Kentucky
- Pfizer Investigational Site - Lexington
Montana
- Pfizer Investigational Site - Billings
Oregon
- Pfizer Investigational Site - Eugene
Pennsylvania
- Pfizer Investigational Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,083 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
What the finished NCT00242710 record still lists
NCT00242710 is an interventional study that assigns participants to a tested intervention. Its 1,083 participants enrollment target places it among the larger protocols in the corpus, below the 1,533-participant average among 84 other Osteoporosis trials with a reported enrollment target (29% lower).
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00242710 lists 9 locations in 8 states (Florida, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT00242710 about?
NCT00242710 is a clinical study titled "Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women". The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
What is the current status of trial NCT00242710?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,083 participants. The study started on 2005-09. Estimated completion is 2008-09.
What conditions does trial NCT00242710 study?
This clinical trial studies the following conditions: Osteoporosis, Endometrial Hyperplasia.
What interventions are being tested in trial NCT00242710?
The interventions under investigation include: Placebo (OTHER), Bazedoxifene/Conjugated Estrogen (DRUG), CE 0.45 mg/MPA 1.5mg (DRUG).
Who is sponsoring clinical trial NCT00242710?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00242710 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Hawaii, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00242710's enrollment target sits among peer trials
1,083 14th of 84 higher than 71 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
COMPLETED · Phase 3
-
Secondary Prevention of Osteoporosis
COMPLETED · Phase 3
-
HORIZON-PFT: Pivotal Fracture Trial
COMPLETED · Phase 3
-
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia